John S Welch

List of Publications by Year
in descending order

87	19,632	186265	102487
papers	citations	28 h-index	66 g-index

89	89	89	27094
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells. Haematologica, 2022, 107, 417-426.	3.5	3
2	Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. Leukemia, 2022, 36, 935-945.	7.2	18
3	A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis. Haematologica, 2022, , .	3.5	0
4	Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. Haematologica, 2022, 107, 1709-1713.	3.5	2
5	Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine. Experimental Hematology, 2022, , .	0.4	5
6	TP53 and the star-crossed lovers MDS and AML. Blood, 2022, 139, 2265-2266.	1.4	2
7	Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. Blood Cancer Discovery, 2022, 3, 330-345.	5.0	10
8	Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematologica, 2021, 106, 1008-1021.	3.5	11
9	Cytokine exposure mediates transcriptional activation of the orphan nuclear receptor Nur77 in hematopoietic cells. Journal of Biological Chemistry, 2021, 297, 101240.	3.4	1
10	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precision Oncology, 2021, 5, 191-203.	3.0	4
11	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. Blood, 2021, 138, 800-800.	1.4	0
12	Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB). International Journal of Molecular Sciences, 2021, 22, 12371.	4.1	2
13	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood, 2021, 138, 1270-1270.	1.4	1
14	Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood, 2021, 138, 694-694.	1.4	0
15	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736.	4.6	201
16	Expanding dasatinib beyond KIT in acute myeloid leukemia. Haematologica, 2020, 105, 2708-2710.	3.5	2
17	Molecular Profiling of Decitabine Response in MDS and AML Patients. Blood, 2020, 136, 40-40.	1.4	0
18	Identification of AML/MDS Drug Sensitization By In Vivo Chemotherapy Administration. Blood, 2020, 136, 32-33.	1.4	0

#	Article	IF	Citations
19	TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies. Haematologica, 2019, 104, e345-e348.	3.5	21
20	Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. Haematologica, 2019, 104, e170-e173.	3.5	2
21	Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy. Cancers, 2019, 11, 1915.	3.7	49
22	Smc3 is required for mouse embryonic and adult hematopoiesis. Experimental Hematology, 2019, 70, 70-84.e6.	0.4	12
23	Exome analysis of treatmentâ€related <scp>AML</scp> after <scp>APL</scp> suggests secondary evolution. British Journal of Haematology, 2019, 185, 984-987.	2.5	1
24	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637.	1.4	15
25	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood, 2019, 134, 645-645.	1.4	9
26	Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood, 2019, 134, 738-738.	1.4	3
27	Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia. Blood, 2019, 134, 2677-2677.	1.4	0
28	Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of TET2 Mutant AML. Blood, 2019, 134, 3755-3755.	1.4	0
29	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	12.8	150
30	Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Haematologica, 2018, 103, e270-e273.	3.5	1
31	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 555-573.	3.8	71
32	A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. Blood Advances, 2018, 2, 1295-1299.	5.2	25
33	Patterns of mutations in TP53 mutated AML. Best Practice and Research in Clinical Haematology, 2018, 31, 379-383.	1.7	43
34	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine, 2018, 379, 2330-2341.	27.0	322
35	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	27.0	93
36	Integrative omics analyses broaden treatment targets in human cancer. Genome Medicine, 2018, 10, 60.	8.2	17

#	Article	IF	Citations
37	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 286-286.	1.4	19
38	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	1.4	0
39	Decitabine inTP53-Mutated AML. New England Journal of Medicine, 2017, 376, 796-798.	27.0	45
40	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell, 2017, 168, 801-816.e13.	28.9	177
41	Endogenous retinoid X receptor ligands in mouse hematopoietic cells. Science Signaling, 2017, 10, .	3.6	18
42	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10â€day decitabine regimen. Cancer Medicine, 2017, 6, 2814-2821.	2.8	21
43	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	1.4	94
44	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
45	Hand-foot syndrome following decitabine. Annals of Hematology, 2016, 95, 535-536.	1.8	3
46	Pathways of retinoid synthesis in mouse macrophages and bone marrow cells. Journal of Leukocyte Biology, 2016, 99, 797-810.	3.3	12
47	Smc3 Haploinsufficiency and Smc3 Deletion Alter Hematopoiesis In Vivo. Blood, 2016, 128, 2903-2903.	1.4	0
48	Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 1528-1528.	1.4	4
49	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207
50	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	12.8	243
51	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 811.	7.4	302
52	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015, 518, 552-555.	27.8	685
53	A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results. Blood, 2015, 126, 1935-1935.	1.4	2
54	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. Blood, 2015, 126, 610-610.	1.4	3

#	Article	IF	Citations
55	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
56	Pathways of Retinoid Synthesis in Mouse Bone Marrow-Derived Macrophages and Hematopoietic Progenitors. Blood, 2015, 126, 1009-1009.	1.4	3
57	Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients. Blood, 2015, 126, 686-686.	1.4	0
58	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. PLoS Computational Biology, 2014, 10, e1003665.	3.2	400
59	Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 2014, 20, 1472-1478.	30.7	1,533
60	Mutation Position Within Evolutionary Subclonal Architecture in AML. Seminars in Hematology, 2014, 51, 273-281.	3.4	17
61	A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American Journal of Hematology, 2014, 89, E103-8.	4.1	15
62	Natural Ligands for Rxra, but Not Rara, Are Observed in Mouse Bone Marrow Cells, and Are Augmented in Response to 5FU and GCSF. Blood, 2014, 124, 4339-4339.	1.4	0
63	Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502, 333-339.	27.8	3,695
64	Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine, 2013, 368, 2059-2074.	27.0	4,139
65	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. Blood, 2013, 122, 3931-3931.	1.4	0
66	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816.	1.4	0
67	Solid, Low-Attenuation Splenic Lesions on Computed Tomography in Patients With Indolent Lymphoma Often Signal Transformation: A Series of Ten Patients. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 452-454.	0.4	0
68	Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481, 506-510.	27.8	1,795
69	The Origin and Evolution of Mutations in Acute Myeloid Leukemia. Cell, 2012, 150, 264-278.	28.9	1,365
70	Deep Digital Sequencing Identifies an AML Subclone with Enhanced in Vitro and in Vivo Growth Properties Associated with Disease Relapse. Blood, 2012, 120, 407-407.	1.4	0
71	Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Blood, 2011, 117, 2460-2468.	1.4	17
72	Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. American Journal of Hematology, 2011, 86, 796-800.	4.1	39

#	Article	IF	Citations
73	Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene. JAMA - Journal of the American Medical Association, 2011, 305, 1577.	7.4	233
74	Genomics of AML: Clinical Applications of Next-Generation Sequencing. Hematology American Society of Hematology Education Program, 2011, 2011, 30-35.	2.5	37
75	PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. Journal of Clinical Investigation, 2011, 121, 1636-1645.	8.2	35
76	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. Journal of Clinical Investigation, 2011, 121, 1445-1455.	8.2	91
77	Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes. Blood, 2011, 118, 404-404.	1.4	1
78	A protease-resistant PML-RARÎ± has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood, 2010, 116, 3604-3610.	1.4	12
79	DNMT3AMutations in Acute Myeloid Leukemia. New England Journal of Medicine, 2010, 363, 2424-2433.	27.0	1,777
80	A Phase I Dose-Escalation Study of Combination Decitabine, Arsenic Trioxide and Ascorbic Acid In Patients with MDS and AML. Blood, 2010, 116, 2148-2148.	1.4	1
81	Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes. Blood, 2010, 116, 99-99.	1.4	9
82	Resolution of a Clinical Dilemma with Whole Genome Sequencing, and Discovery of a New Mechanism for Generating PML-Rara: Insertional Fusion. Blood, 2010, 116, 2755-2755.	1.4	0
83	The Effect of Rara Haploinsufficiency in a Mouse Model of Acute Promyelocytic Leukemia.. Blood, 2009, 114, 3475-3475.	1.4	0
84	Expression of PML-RARÎ± by the Murine PML Locus Leads to Myeloid Self-Renewal, Clonal Expansion and Morphologic Promyelocytic Leukemia.. Blood, 2008, 112, 932-932.	1.4	1
85	A Protease-Resistant PML-RARÎ± Has Increased Leukemogenic Potential in a Murine Model of Acute Promyelocytic Leukemia (APL).. Blood, 2008, 112, 930-930.	1.4	0
86	Cladribine in the Treatment of Acute Myeloid Leukemia. Blood, 2008, 112, 4032-4032.	1.4	0
87	Interleukin-4-dependent production of PPAR-Î³ ligands in macrophages by 12/15-lipoxygenase. Nature, 1999, 400, 378-382.	27.8	822